AstraZeneca and Neurimmune to develop and commercialise NI006
Investigational human monoclonal antibody in Phase Ib development for the treatment of transthyretin amyloid cardiomyopathy, a systemic, progressive and fatal condition
Investigational human monoclonal antibody in Phase Ib development for the treatment of transthyretin amyloid cardiomyopathy, a systemic, progressive and fatal condition
The brand is now available pan-India through their distribution partner
After double lung transplantation, he was discharged without supplemental oxygen on the eleventh day
It is the generic version of molnupiravir
Entacapone tablets USP, 200 mg have an estimated market size of US$ 10.5 million for twelve months ending September 2021, according to IQVIA
Biogen paid Ionis a US $ 60 million one-time upfront payment
The virtual world makes it possible to visualize, test, understand and predict what cannot be seen, before a patient is treated
BPZE1 is the most advanced next-generation pertussis vaccine currently in clinical development
Upon completion of successful human trials and regulatory approval, the joint venture's goal is to start delivering the second-generation vaccine in 2022 as soon as is practically possible
This next-generation CAR T construct was designed to improve the tolerability profile of conventional CD19 CAR Ts and developed in the laboratory of James N. Kochenderfer, M.D., at the National Cancer Institute, part of the NIH, the same laboratory that discovered axicabtagene ciloleucel
Subscribe To Our Newsletter & Stay Updated